TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 AMD
Advanced Micro Devices
-- 119.210 OXY
Occidental Petroleum
-- 47.130 
Health Care Sector Update for 08/24/2022: SPRC,GKOS,BCDA
$Ultra Nasdaq Biotechnology Proshares (BIB.US)$ was climbing 1.5%.
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after Wednesday saying it secured an exclusive global license from iVeena Delivery Systems to develop and commercialize its IVMED-80 drug candidate to treat corneal disorders in exchange for a $10 million upfront payment as well as potential development and sales milestone payments.
$BioCardia (BCDA.US)$ fell 1.9% this afternoon, reversing a nearly 7% gain, after the regenerative medicine company Wednesday said it would provide its biotherapeutic delivery product candidates to privately held BlueRock Therapeutics in exchange for an unspecified upfront payment. BioCardia also has the option to negotiate a nonexclusive global license combining its biotherapeutic delivery product candidates with BlueRock's engineered cell therapies in certain cardiac indications.
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after Wednesday saying it secured an exclusive global license from iVeena Delivery Systems to develop and commercialize its IVMED-80 drug candidate to treat corneal disorders in exchange for a $10 million upfront payment as well as potential development and sales milestone payments.
$BioCardia (BCDA.US)$ fell 1.9% this afternoon, reversing a nearly 7% gain, after the regenerative medicine company Wednesday said it would provide its biotherapeutic delivery product candidates to privately held BlueRock Therapeutics in exchange for an unspecified upfront payment. BioCardia also has the option to negotiate a nonexclusive global license combining its biotherapeutic delivery product candidates with BlueRock's engineered cell therapies in certain cardiac indications.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment